There are currently 1109 clinical trials in Cincinnati, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Cincinnati Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424, 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
02/25/2025
Locations: Riverhills Healthcare, Inc dba Riverhills Neuroscience, Cincinnati, Ohio
Conditions: Parkinson Disease
Register for Updates
Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
NCT06818474
Recruiting
use of lanadelumab in patients with acquired angioedema
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Bernstein Clinical Research Center, LLC, Cincinnati, Ohio
Conditions: Angioedema
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio +1 locations
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
A Study of Pitolisant in Patients with Prader-Willi Syndrome
NCT06366464
Recruiting
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with Prader-Willi syndrome. The primary objective of this study is to evaluate the efficacy of pitolisant in treating excessive daytime sleepiness (EDS) in patients ≥6 years of age with Prader-Willi syndrome. Secondary objectives include assessing the impact of pitolisant on: * Irritable and disruptive behaviors * Hyperphagia *... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
02/24/2025
Locations: CTI Clinical Research Center, Cincinnati, Ohio
Conditions: Prader-Willi Syndrome
Register for Updates
Gene Therapy for B-Cell Acute Lymphoblastic Leukemia
NCT06533579
Recruiting
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia (ALL).
Gender:
ALL
Ages:
Between 13 years and 90 years
Trial Updated:
02/24/2025
Locations: Oncology Hematology Care, Cincinnati, Ohio
Conditions: B-cell Acute Lymphoblastic Leukemia
Register for Updates
Pediatric Post-Approval Registry
NCT04457154
Recruiting
This registry is a prospective, multi-center, single-arm study of pediatric subjects (ages 18-21 years) who are undergoing implant of the Inspire Upper Airway Stimulation (UAS) System for the treatment of moderate or severe obstructive sleep apnea (OSA). Implanted subjects will be followed for 5 years post-implant.
Gender:
ALL
Ages:
Between 18 years and 21 years
Trial Updated:
02/24/2025
Locations: Cincinnati Childrens Hospital, Cincinnati, Ohio
Conditions: Obstructive Sleep Apnea
Register for Updates
SPEARHEAD-3 Pediatric Study
NCT05642455
Recruiting
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-21 years of age with advanced cancers
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
02/24/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma, Osteosarcoma
Register for Updates
PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm
NCT06445608
Recruiting
This purpose of this trial is to demonstrate 30 day safety and effectiveness outcomes of the KARDION CORY P4 System in subjects who require hemodynamic support during a high-risk PCI procedure.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/21/2025
Locations: The Lindner Research Center at The Christ Hospital, Cincinnati, Ohio
Conditions: Coronary Artery Disease
Register for Updates
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
NCT05703971
Recruiting
This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Oncology_Hematology Care Clinical Trials, LLC, Cincinnati, Ohio +3 locations
Conditions: Small Cell Lung Cancer Extensive Stage
Register for Updates
Positive Peers Intervention Clinical Trial
NCT06388109
Recruiting
The goal of this clinical trial is to learn if the Positive Peers mobile app intervention increases rates of viral suppression in young (13-34 y/o) persons with HIV. Does use of the Positive Peers app improve viral suppression among young minority persons with HIV? What user characteristics are associated with a) viral suppression, b) retention in care, and c) perceived HIV-related stigma? Participants will: * download the mobile app onto their personal smartphone * Use the mobile app as they... Read More
Gender:
ALL
Ages:
Between 13 years and 34 years
Trial Updated:
02/21/2025
Locations: Equitas Health, Cincinnati, Ohio
Conditions: HIV Infections
Register for Updates
Peri-operative Tamsulosin and Impact on Voiding Trial After Same-day Urogynecology Surgery
NCT06843538
Recruiting
The purpose of this research study is to determine if taking tamsulosin preoperatively decreases your chances of being discharged after surgery with a Foley catheter (flexible tube that drains urine from the bladder into a collection bag).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: TriHealth, Cincinnati, Ohio
Conditions: Postoperative Urinary Retention (POUR)
Register for Updates
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510
Recruiting
The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once eve... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: University of Cincinnati Cancer Center - 1107, Cincinnati, Ohio
Conditions: Non Small Cell Lung Cancer
Register for Updates